![The Lancet Publishes Positive Results from Capricor's Phase 2 Study of CAP- 1002 in Late-Stage Duchenne - Parent Project Muscular Dystrophy The Lancet Publishes Positive Results from Capricor's Phase 2 Study of CAP- 1002 in Late-Stage Duchenne - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2021/09/capricor-blog.png)
The Lancet Publishes Positive Results from Capricor's Phase 2 Study of CAP- 1002 in Late-Stage Duchenne - Parent Project Muscular Dystrophy
![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/a94a0d96-3434-4a33-8926-adff3b15c63f/gr2_lrg.gif)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
![Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne](https://www.actionduchenne.org/wp-content/uploads/2019/04/getimage-17-800x500.png)
Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne
![Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2022/01/capricor-ns-blog2.png)
Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy
![StudyPages - A Study of Experimental Cell Therapy (CAP-1002) in Patients With Duchenne Muscular Dystrophy (DMD) StudyPages - A Study of Experimental Cell Therapy (CAP-1002) in Patients With Duchenne Muscular Dystrophy (DMD)](https://yuzu-studypages-prod-east.s3.amazonaws.com/study_banners/1201.jpg)
StudyPages - A Study of Experimental Cell Therapy (CAP-1002) in Patients With Duchenne Muscular Dystrophy (DMD)
![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/fe84eaa0-ba78-4885-9356-e90540aee628/gr3_lrg.jpg)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/2a177874-d81b-454a-a2df-0ca072caa517/gr4.jpg)